VANCOUVER, British Columbia, March 26, 2009 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX.V:BTI) is pleased to announce that it has retained Crescent Communications of Westport, Connecticut, USA to undertake investor relations activities on behalf of the Company.
Crescent Communications is a Market Research and Investor Relations firm specializing in emerging market companies. Crescent has successfully increased shareholder value and awareness for clients for the past twenty-six years. Crescent provides a full-range of investor relations, research, and consulting services to publicly traded companies seeking to broaden their investor base in the financial community.
"We are delighted to retain Crescent Communications for investor relations in the USA," says CEO Rob Hutchison. "In particular, Crescent will introduce the Company to analysts, private investors, brokers and institutional investors who form a part of the substantial biotech investment community in the U.S."
"I am thrilled to represent biOasis to the financial community in the United States," asserts David Long, founder of Crescent. "We have had great success with notable companies such as BioChem Pharma and ID Biomedical Corp. We are confident of the interest biOasis will generate with our investor contacts and look forward to supporting the Company at this vital juncture in its emergence to the U.S. financial markets."
Crescent will receive monthly remuneration of US$6,500 and 200,000 incentive stock options, exercisable at $0.35 for 5 years from the date of grant, all subject to the approval of the TSX Venture Exchange. The options are subject to vesting provisions.
ABOUT BIOASIS:
biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases. It has extensive and comprehensive intellectual property ("IP") which it obtained from the University of British Columbia. The Company's initial area of focus will be on the utilization of the IP to pursue a biomarker for the diagnosis of Alzheimer's disease. The IP has been corroborated in double blinded and successive multi-site clinical trials.
According to the Centers for Disease Control and Prevention ("CDC"), Alzheimer's disease was listed as the "underlying cause of death" for 65,829 Americans in 2004. It was the seventh leading cause of death for people of all ages and the fifth leading cause of death in people age 65 and older.
To find out more about biOasis Technologies Inc. visit www.bioasis.ca.
Forward Looking Statements
Statements in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the Company's ability to raise additional funding and the potential dilutive effects thereof, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the strength of intellectual property, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
On Behalf of the Board of Directors
Robin Hutchison Director and CEO (604) 542-5059 rob@bioasis.ca
"The TSX Venture Exchange has neither approved nor disapproved the contents of this press release."